Sonoma Pharmaceuticals Appoints Biotech Finance Veteran Vanessa Jacoby to Board, Audit Chair

summarizeSummary

Sonoma Pharmaceuticals announced the retirement of long-serving director Dr. Jay Birnbaum, who will transition to a consulting role, and the appointment of Ms. Vanessa Jacoby, a seasoned financial executive in the biotechnology sector, to its Board of Directors and as Audit Committee Chairperson.

check_boxKey Events

• Director Retirement

  Dr. Jay Birnbaum retired from the Board of Directors, effective January 28, 2026, after serving since April 2007.

• Consulting Agreement for Outgoing Director

  Dr. Birnbaum will continue to serve the company for one year under a consulting agreement, receiving 5,000 Restricted Stock Units (RSUs) per quarter, totaling 20,000 RSUs.

• New Independent Director Appointed

  Ms. Vanessa Jacoby, a financial executive with extensive experience in the biotechnology and life science sectors, was appointed as an independent director.

• Key Committee Leadership

  Ms. Jacoby was appointed Chairperson of the Audit Committee and a non-chairperson member of the Compensation Committee.

auto_awesomeAnalysis

The appointment of Ms. Vanessa Jacoby, a Certified Public Accountant with extensive experience as a senior financial executive in the biotechnology and life science sectors, is a significant positive for Sonoma Pharmaceuticals. Her expertise will be particularly valuable as she assumes the role of Audit Committee Chairperson, enhancing the company's financial oversight and corporate governance. While Dr. Jay Birnbaum's retirement marks the departure of a long-serving director, his transition to a consulting agreement ensures continued access to his institutional knowledge, mitigating potential disruption. The revised director compensation plan provides flexibility for future board appointments.